1501Tip A Phase III Global Study of Telisotuzumab Vedotin Versus Docetaxel in Previously Treated Patients with C-Met Overexpressing, EGFR Wildtype, Locally Advanced/metastatic Nonsquamous NSCLC (telimet NSCLC-01)
Annals of Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined